Background: Coronary Artery Disease (CAD) is the most common reason for death in the
western hemisphere. Therefore, a well-functioning risk-management has been established over the past
decades with uprising interest in ‘novel’ biomarkers to predict adverse coronary events and detect patients
with subclinical CAD. This review will focus on selected biomarkers belonging to the family of
inflammatory markers (fibrinogen or hs-CRP) or to the family of lipid-associated markers (Lipoprotein
associated PA2 or Lipoprotein a) and organ-specific biomarkers (hs-troponin, Cystatin C or NTproBNP).
Methods: This review is based on a pubmed search focusing on the biomarkers fibrinogen, hs-CRP,
Lipoprotein associated PA2, Lipoprotein a, hs-troponin, NT-proBNP and Cystatin C.
Results: The search retrieved 149 references containing meta-analysis, prospective and retrospective
studies concerning the usage of the selected biomarkers in risk prediction and detection of CAD. Despite
clinical studies, current guidelines of the European Society of Cardiology (ESC), the American
Heart Association (AHA) and the Canadian Cardiovascular Society (CCS) were analyzed regarding
their recommendation of the implementation of biomarkers in clinical routine. The review identified
promising stand-alone biomarkers and multi-marker risk models for CAD patients.
Conclusion: Novel biomarkers detect patients at risk beyond established risk scores. However, an ideal
biomarker fulfilling all necessary criteria does still not exist.